Patents by Inventor Scott Albert Uhland
Scott Albert Uhland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10328203Abstract: A system for use with a drug delivery device includes a sensor unit and a deactivation unit operatively coupled to an output of the sensor unit and to a drug-retaining region of the drug delivery device, wherein the drug-retaining region contains a drug. The sensor unit is configured to detect a characteristic of a local environment and generate an output corresponding to a value of the detected characteristic. The deactivation unit is configured to render the drug ineffective when the output of the sensor unit satisfies a predetermined condition.Type: GrantFiled: October 20, 2016Date of Patent: June 25, 2019Assignee: PALO ALTO RESEARCH CENTER INCORPORATEDInventors: Scott Albert Uhland, Eric Peeters, Bryan Thomas Preas, Joerg Martini
-
Publication number: 20170035970Abstract: A system for use with a drug delivery device includes a sensor unit and a deactivation unit operatively coupled to an output of the sensor unit and to a drug-retaining region of the drug delivery device, wherein the drug-retaining region contains a drug. The sensor unit is configured to detect a characteristic of a local environment and generate an output corresponding to a value of the detected characteristic. The deactivation unit is configured to render the drug ineffective when the output of the sensor unit satisfies a predetermined condition.Type: ApplicationFiled: October 20, 2016Publication date: February 9, 2017Inventors: SCOTT ALBERT UHLAND, ERIC PEETERS, BRYAN THOMAS PREAS, JOERG MARTINI
-
Patent number: 9480795Abstract: A system for use with a drug delivery device includes a sensor unit and a deactivation unit operatively coupled to an output of the sensor unit and to a drug-retaining region of the drug delivery device, wherein the drug-retaining region contains a drug. The sensor unit is configured to detect a characteristic of a local environment and generate an output corresponding to a value of the detected characteristic. The deactivation unit is configured to render the drug ineffective when the output of the sensor unit satisfies a predetermined condition.Type: GrantFiled: January 21, 2009Date of Patent: November 1, 2016Assignee: PALO ALTO RESEARCH CENTER INCORPORATEDInventors: Scott Albert Uhland, Eric Peeters, Bryan Thomas Preas, Joerg Martini
-
Patent number: 8642830Abstract: A drug deactivation system according to some embodiments includes at least one drug-retaining region of a drug delivery device and at least one energy source coupled to the at least one drug-retaining region. The at least one drug-retaining region may be configured to retain a drug. The at least one energy source may be configured to transmit energy to the drug. The drug is capable of being rendered ineffective in the presence of the transmitted energy.Type: GrantFiled: July 3, 2012Date of Patent: February 4, 2014Assignee: Palo Alto Research Center IncorporatedInventors: Scott Albert Uhland, Eric Peeters, Francisco E. Torres, Philipp Helmut Schmaelzle
-
Patent number: 8317749Abstract: A method of enabling administration of a drug includes determining, within a drug-transfer device including cells, a location of at least one cell and generating information identifying the determined location. A user may be provided with the drug-transfer device. The drug is retained within the at least one cell when the user is provided with the drug-transfer device. The method also includes encoding a key with the information and providing the user with the key before, after or when the user is provided with the drug-transfer device. Drug retained within the at least one cell is selectively releasable when the key is operably proximate to the drug-transfer device and is encoded with the information. The key can be encoded with the information before and/or after being provided to the user. In some embodiments, the key is encoded based on instructions transmitted over a network.Type: GrantFiled: June 30, 2009Date of Patent: November 27, 2012Assignee: Palo Alto Research Center IncorporatedInventors: Philipp Helmut Schmaelzle, Scott Albert Uhland
-
Patent number: 8313456Abstract: Devices capable of deterring or preventing bulk extraction of drugs from, for example, drug-delivery systems are exemplarily disclosed. In one embodiment, such a device may include a package releasably retaining a drug and an agent. The agent is configured to suppress a physiological effect of the drug when the agent contacts the drug or is coadministered with the drug. The cell package is configured such that an amount of the drug is selectively releasable with respect to the agent when the package is operably proximate to an encoded key. The package, however, may be configured to impose a relatively high likelihood that either the drug will not be accessed or the drug will be contaminated by the agent if access to the contents of the package is sought without the use of an encoded key.Type: GrantFiled: June 30, 2009Date of Patent: November 20, 2012Assignee: Palo Alto Research Center IncorporatedInventors: Philipp Helmut Schmaelzle, Scott Albert Uhland
-
Publication number: 20120277514Abstract: A drug deactivation system according to some embodiments includes at least one drug-retaining region of a drug delivery device and at least one energy source coupled to the at least one drug-retaining region. The at least one drug-retaining region may be configured to retain a drug. The at least one energy source may be configured to transmit energy to the drug. The drug is capable of being rendered ineffective in the presence of the transmitted energy.Type: ApplicationFiled: July 3, 2012Publication date: November 1, 2012Applicant: Palo Alto Research Center IncorporatedInventors: Scott Albert Uhland, Eric Peeters, Francisco E. Torres, Philipp Helmut Schmaelzle
-
Publication number: 20120248092Abstract: A thermistor has a mixture of a temperature sensitive material and a conductive material, and an electrode in electrical contact with the mixture. A method of manufacturing a thermistor includes depositing conductive contacts onto a substrate, printing a thermistor mixture of temperature sensitive material and a conductive material over the contact, and annealing the thermistor mixture to produce a flexible thermistor on the conductive contacts.Type: ApplicationFiled: March 30, 2011Publication date: October 4, 2012Applicant: PALO ALTO RESEARCH CENTER INCORPORATEDInventors: Scott Albert Uhland, Jurgen H. Daniel, Gregory Lewis Whiting
-
Patent number: 8257736Abstract: A method of fabricating a drug-transfer device includes forming a package having a first component retaining multiple volumes of a drug and a second component retaining an agent. The first component and the second component are integrally formed together. The agent is configured to suppress a physiological effect of the drug when the agent contacts the drug or is coadministered with the drug. The method allows exterior surfaces of the first and second components to be cleanable (e.g., prior to final assembly). After such cleaning, either no or substantially no amount of drug and agent is present outside the package. According to some embodiments, the package may be fabricated such that either no or substantially no amount of the drug is present within the second component and such that either no or substantially no amount of the agent is present within the first component.Type: GrantFiled: June 30, 2009Date of Patent: September 4, 2012Assignee: Palo Alto Research Center IncorporatedInventors: Philipp Helmut Schmaelzle, Scott Albert Uhland
-
Patent number: 8236238Abstract: A drug deactivation system according to some embodiments includes at least one drug-retaining region of a drug delivery device and at least one energy source coupled to the at least one drug-retaining region. The at least one drug-retaining region may be configured to retain a drug. The at least one energy source may be configured to transmit energy to the drug. The drug is capable of being rendered ineffective in the presence of the transmitted energy.Type: GrantFiled: January 21, 2009Date of Patent: August 7, 2012Assignee: Palo Alto Research Center IncorporatedInventors: Scott Albert Uhland, Eric Peeters, Francisco E. Torres, Philipp Helmut Schmaelzle
-
Publication number: 20100331772Abstract: Devices capable of deterring or preventing bulk extraction of drugs from, for example, drug-delivery systems are exemplarily disclosed. In one embodiment, such a device may include a package releasably retaining a drug and an agent. The agent is configured to suppress a physiological effect of the drug when the agent contacts the drug or is coadministered with the drug. The cell package is configured such that an amount of the drug is selectively releasable with respect to the agent when the package is operably proximate to an encoded key. The package, however, may be configured to impose a relatively high likelihood that either the drug will not be accessed or the drug will be contaminated by the agent if access to the contents of the package is sought without the use of an encoded key.Type: ApplicationFiled: June 30, 2009Publication date: December 30, 2010Applicant: PALO ALTO RESEARCH CENTER INCORPORATEDInventors: Philipp Helmut Schmaelzle, Scott Albert Uhland
-
Publication number: 20100328024Abstract: A method of enabling administration of a drug includes determining, within a drug-transfer device including cells, a location of at least one cell and generating information identifying the determined location. A user may be provided with the drug-transfer device. The drug is retained within the at least one cell when the user is provided with the drug-transfer device. The method also includes encoding a key with the information and providing the user with the key before, after or when the user is provided with the drug-transfer device. Drug retained within the at least one cell is selectively releasable when the key is operably proximate to the drug-transfer device and is encoded with the information. The key can be encoded with the information before and/or after being provided to the user. In some embodiments, the key is encoded based on instructions transmitted over a network.Type: ApplicationFiled: June 30, 2009Publication date: December 30, 2010Applicant: PALO ALTO RESEARCH CENTER INCORPORATEDInventors: Philipp Helmut Schmaelzle, Scott Albert Uhland
-
Publication number: 20100326020Abstract: A method of fabricating a drug-transfer device includes forming a package having a first component retaining multiple volumes of a drug and a second component retaining an agent. The first component and the second component are integrally formed together. The agent is configured to suppress a physiological effect of the drug when the agent contacts the drug or is coadministered with the drug. The method allows exterior surfaces of the first and second components to be cleanable (e.g., prior to final assembly). After such cleaning, either no or substantially no amount of drug and agent is present outside the package. According to some embodiments, the package may be fabricated such that either no or substantially no amount of the drug is present within the second component and such that either no or substantially no amount of the agent is present within the first component.Type: ApplicationFiled: June 30, 2009Publication date: December 30, 2010Applicant: PALO ALTO RESEARCH CENTER INCORPORATEDInventors: Philipp Helmut Schmaelzle, Scott Albert Uhland
-
Patent number: 7838715Abstract: A drug deactivation system according to some embodiments includes at least one degradable capsule exposed to at least one drug-retaining region of a drug delivery device and an agent. The agent is configured to render a drug ineffective upon degradation of the at least one capsule. The at least one drug-retaining region is configured to retain one of the drug and the agent and the at least one capsule is configured to retain the other of the drug and the agent.Type: GrantFiled: January 21, 2009Date of Patent: November 23, 2010Assignee: Palo Alto Research Center IncorporatedInventors: Scott Albert Uhland, Eric Peeters, Francisco E. Torres, Philipp Helmut Schmaelzle
-
Publication number: 20100185037Abstract: A drug deactivation system according to some embodiments includes at least one drug-retaining region of a drug delivery device and at least one energy source coupled to the at least one drug-retaining region. The at least one drug-retaining region may be configured to retain a drug. The at least one energy source may be configured to transmit energy to the drug. The drug is capable of being rendered ineffective in the presence of the transmitted energy.Type: ApplicationFiled: January 21, 2009Publication date: July 22, 2010Applicant: Palo Alto Research Center IncorporatedInventors: Scott Albert Uhland, Eric Peeters, Francisco E. Torres, Philipp Helmut Schmaelzle
-
Publication number: 20100185143Abstract: A system for use with a drug delivery device includes a sensor unit and a deactivation unit operatively coupled to an output of the sensor unit and to a drug-retaining region of the drug delivery device, wherein the drug-retaining region contains a drug. The sensor unit is configured to detect a characteristic of a local environment and generate an output corresponding to a value of the detected characteristic. The deactivation unit is configured to render the drug ineffective when the output of the sensor unit satisfies a predetermined condition.Type: ApplicationFiled: January 21, 2009Publication date: July 22, 2010Applicant: PALO ALTO RESEARCH CENTER INCORPORATEDInventors: Scott Albert Uhland, Eric Peeters, Bryan Thomas Preas, Joerg Martini
-
Publication number: 20100185038Abstract: A drug deactivation system according to some embodiments includes at least one degradable capsule exposed to at least one drug-retaining region of a drug delivery device and an agent. The agent is configured to render a drug ineffective upon degradation of the at least one capsule. The at least one drug-retaining region is configured to retain one of the drug and the agent and the at least one capsule is configured to retain the other of the drug and the agent.Type: ApplicationFiled: January 21, 2009Publication date: July 22, 2010Applicant: PALO ALTO RESEARCH CENTER INCORPORATEDInventors: Scott Albert Uhland, Eric Peeters, Francisco E. Torres, Philipp Helmut Schmaelzle
-
Publication number: 20090112188Abstract: Microchip devices are provided that include a substrate; a plurality of reservoirs in the substrate, each reservoir defining an internal volume; and a reservoir cap positioned on or in each of the reservoirs bounding the internal volume from an external environment, the reservoir cap being formed of a material that undergoes a phase change upon heating, wherein the internal volume can communicate with the external environment upon heating said reservoir cap to cause said reservoir cap to undergo a phase change and rupture.Type: ApplicationFiled: January 5, 2009Publication date: April 30, 2009Applicant: MICROCHIPS, INC.Inventors: John T. Santini, JR., Michael J. Cima, Scott Albert Uhland
-
Patent number: 7473248Abstract: Methods are provided for controlled reservoir opening, including the steps of (a) providing a biocompatible implantable device which comprises at least one substrate, a plurality of reservoirs in the substrate, reservoir caps each of which covers one of the reservoirs, and molecules sealed inside the reservoirs; and (b) selectively heating each reservoir cap in an amount effective to rupture the reservoir cap and open the reservoir. In another embodiment, the method steps include (a) implanting into a patient a biocompatible device which comprises at least one substrate, a plurality of reservoirs in the substrate, reservoir caps each of which covers one of the reservoirs, and molecules sealed inside the reservoirs; and (b) selectively heating each reservoir cap in an amount effective to rupture the reservoir cap and open the reservoir.Type: GrantFiled: December 29, 2003Date of Patent: January 6, 2009Assignee: MicroCHIPS, Inc.Inventors: John T. Santini, Jr., Michael J. Cima, Scott Albert Uhland
-
Publication number: 20040143236Abstract: Methods are provided for controlled reservoir opening, including the steps of (a) providing a biocompatible implantable device which comprises at least one substrate, a plurality of reservoirs in the substrate, reservoir caps each of which covers one of the reservoirs, and molecules sealed inside the reservoirs; and (b) selectively heating each reservoir cap in an amount effective to rupture the reservoir cap and open the reservoir. In another embodiment, the method steps include (a) implanting into a patient a biocompatible device which comprises at least one substrate, a plurality of reservoirs in the substrate, reservoir caps each of which covers one of the reservoirs, and molecules sealed inside the reservoirs; and (b) selectively heating each reservoir cap in an amount effective to rupture the reservoir cap and open the reservoir.Type: ApplicationFiled: December 29, 2003Publication date: July 22, 2004Inventors: John T. Santini, Michael J. Cima, Scott Albert Uhland